CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2025
0mins
Source: Globenewswire
Biliary Tract Cancer and Plogosertib: Cyclacel Pharmaceuticals announced promising preclinical results showing that plogosertib, a PLK1 inhibitor, effectively induces apoptosis in biliary tract cancer (BTC) cells, particularly those with high BUBR1 expression, suggesting its potential as a treatment option.
Clinical Implications: The study indicates that targeting PLK1 could be an effective strategy for BTC treatment, especially when combined with ATR inhibitors, addressing the urgent need for effective therapies for patients with relapsed or unresectable BTC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
